 VANCOUVER, Wash., June 28, 2022 GLOBE NEWSWIRE -- Synlogic, Inc. Nasdaq: SYBX, a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today it will participate at the National PKU Alliances NPKUA biennial conference July 7-10, 2022 in Vancouver, Washington. As an event sponsor, Synlogic has been invited to present during the session Whats New in PKU? Emerging Therapies, Research, Foods Beyond. In addition, the team will share data on dietary protein intake in PKU patients during a poster presentation. 